Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Alpha Genesis Expands GLP Capacity Following Multi-Million-Dollar Investment to Accelerate IND-Enabling Nonhuman Primate Studies

YEMASSEE, SOUTH CAROLINA / ACCESS Newswire / October 14, 2025 / Alpha Genesis, Inc. (AGI), one of the United States' largest nonhuman primate research and breeding organizations, today announced a significant expansion of its Good Laboratory Practice (GLP) program following more than $3 million in new infrastructure and personnel investments. The expansion builds on several years of successful GLP operations and was undertaken to meet increasing client demand for IND-enabling toxicology and pharmacokinetic studies conducted under full regulatory compliance.AGI's Investment in GLP Capacity Supports Global Partners

AGI's Investment in GLP Capacity Supports Global Partners

"Over the past few years, we have conducted a growing number of GLP studies for commercial and government sponsors," said Dr. Xavier Westergaard, Chief Scientific Officer of Alpha Genesis. "We recognized that the biggest challenge many clients face is not finding a qualified partner but getting started quickly. This expansion was about increasing our physical capacity and staffing so that sponsors can initiate a GLP study in weeks rather than months."

AGI's GLP operations are designed to deliver regulatory-grade, audit-ready data packages aligned with FDA 21 CFR Part 58 and OECD GLP Principles. The recent investment strengthens the company's capacity across its entire research infrastructure, enabling faster startup times and greater study volume.

AGI's expanded GLP capabilities include:

  • An experienced, fully independent Quality Assurance Unit that provides continuous oversight of study conduct, inspections, and reporting.

  • Validated electronic data-capture and archival systems that ensure complete traceability and integrity of regulated data.

  • Modernized laboratory and vivarium facilities supporting pharmacokinetic, toxicology, and safety pharmacology studies in rhesus and cynomolgus macaques, with flexibility to accommodate additional nonhuman primate species as required by sponsors.

  • Secure documentation controls with real-time QA review, SOP traceability, and version-controlled regulatory documentation.

  • Expanded technical staff and enhanced training programs to support simultaneous GLP studies with consistent compliance.

AGI's vertically integrated model, which combines on-site breeding, research, and QA oversight, allows the company to offer industry-leading turnaround times. Sponsors can initiate GLP studies in less than one month, compared to the six months or longer typical at many large CROs.

"Our focus has always been on scientific quality and responsiveness," Dr. Westergaard added. "By expanding our GLP facilities and personnel, we have made it possible for sponsors to begin studies almost immediately while maintaining the same regulatory rigor and data integrity expected by the FDA and OECD."

AGI's continued investment in GLP operations strengthens its position as a leading U.S. contract research organization specializing in nonhuman primate regulatory studies. The company's integrated capabilities support IND-enabling toxicology, pharmacokinetic, and safety pharmacology programs with a focus on quality, transparency, and speed.

About Alpha Genesis, Inc. (AGI)

Founded in 2003, Alpha Genesis is a fully integrated nonhuman primate CRO headquartered in Yemassee, South Carolina. AGI provides comprehensive preclinical research, breeding, and contract study services to pharmaceutical, biotechnology, and academic partners worldwide. Its capabilities span discovery pharmacology, GLP toxicology, safety pharmacology, and translational research, all conducted under strict ethical and regulatory oversight. Visit www.AlphaGenesisInc.com for more information.

Contact Information

Dr. Xavier Westergaard
Chief Scientific Officer
xwestergaard@alphagenesisinc.com

.

SOURCE: Alpha Genesis, Inc.



View the original press release on ACCESS Newswire

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.